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Abstract 
 
Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is 
currently treated with BCR-ABL1 tyrosine kinase inhibitors (TKI) in combination with 
chemotherapy. However, most patients develop resistance to TKI through BCR-ABL1-
dependent and -independent mechanisms. Newly developed TKI can target Ph+ ALL 
cells with BCR-ABL1-dependent resistance; however, overcoming BCR-ABL1-
independent mechanisms of resistance remains challenging because transcription 
factors (TF), which are difficult to inhibit, are often involved. We show here that: i) the 
growth of Ph+ ALL cell lines and primary cells is highly dependent on MYB-mediated 
transcriptional upregulation of CDK6, cyclin D3, and BCL2 and ii) restoring their 
expression in MYB-silenced Ph+ ALL cells rescues their impaired proliferation and 
survival. Levels of MYB and CDK6 were highly correlated in adult Ph+ ALL (p=0.00008). 
Moreover, Ph+ ALL cells exhibited a specific requirement for CDK6 but not CDK4 
expression, most likely because, in these cells, CDK6 was predominantly localized in the 
nucleus while CDK4 was almost exclusively cytoplasmic. Consistent with their essential 
role in Ph+ ALL, pharmacological inhibition of CDK6 and BCL2 markedly suppressed 
proliferation, colony formation, and survival of Ph+ ALL cells ex vivo and in mice. In 
summary, these findings provide a proof-of-principle, rational strategy to target the MYB 
"addiction" of Ph+ ALL. 
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Introduction 
B-cell acute lymphoblastic leukemia (ALL) is a molecularly heterogeneous 
malignancy with < 50% 5-year overall survival in adults (1-3). The Philadelphia 
chromosome (Ph) is the most common cytogenetic abnormality in adult ALL with an 
incidence of approximately 30% (4,5).  Standard chemotherapy has a modest impact on 
long-term survival of Ph+ ALL patients, and only bone marrow transplantation extends 
long-term survival in 40-60% of cases (6). Treatment with the tyrosine kinase inhibitor 
(TKI) imatinib and chemotherapy has significantly improved the outcome of Ph+ ALL 
patients (7). However, resistance to imatinib and second-generation TKI develops rapidly 
in most Ph+ ALL patients (8), probably because of secondary mutations in transformed 
B-cell progenitors (9,10) due to aberrant RAG-dependent recombination and/or AID-
dependent somatic hypermutation (11-13). Thus, inhibiting the BCR-ABL1 kinase fails to 
eradicate most Ph+ ALL cell clones due to the activation of BCR-ABL1-dependent and 
independent pathways that need to be targeted for an effective treatment.  
We and others have identified transcription factors (TFs) whose expression/activity 
is required for BCR-ABL1-dependent leukemogenesis (14-18). In particular, BCR-ABL1-
transformed myeloid and lymphoid cells rely on MYB expression more than the normal 
counterpart (15,18), supporting the concept that certain leukemic cells are “addicted” to 
MYB (19-21). This concept was validated in a model of MLL-AF9 AML (22), in which 
partial and transient suppression of MYB expression phenocopied MLL-AF9 withdrawal 
eradicating an aggressive leukemia with no effects on normal myelopoiesis. 
Targeting MYB or relevant protein interactions essential for its activity, is an 
attractive strategy to exploit the MYB dependence of BCR-ABL1-transformed B cells. 
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However, it is inherently difficult to specifically target MYB or its partner proteins, as 
recently identified MYB inhibitors may also function through MYB-independent 
mechanisms. For example, parthenolide inhibited TF activity of MYB and viability of Ph+ 
K562 cells (23); however, this drug has multiple mechanisms of action (24,25), suggesting 
that its effects may be, in part, MYB-independent. Naphthol AS-E phosphate and celastrol 
block the interaction between the MYB transactivation domain and the KIX domain of 
p300, which is required for MYB function (26,27). However, naphthol AS-E phosphate 
induces apoptosis more rapidly and effectively than MYB silencing (26) and celastrol is a 
potent proteasome inhibitor that has pleiotropic effects including the inhibition of NF-κB 
(28,29).  
To overcome these limitations, we sought to identify MYB-dependent pathways 
that may be targeted therapeutically. We show here that cyclin D3, CDK6 and BCL2 are 
relevant MYB targets with essential roles for in vitro growth and leukemogenesis of Ph+ 
ALL cells. These findings provide a “proof of concept” demonstration of how to exploit the 
TF “addiction” of leukemic cells. 
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Methods 
 
Cell culture 
BV173 (CML-lymphoid blast crisis cell line) were kindly provided by Dr N. Donato, 
(NIH), SUP-B15 (Ph+ ALL cell line) were purchased from ATCC, Z181 (Ph+ ALL cell line) 
were kindly provided by Dr. Z. Estrov, (M.D. Anderson Cancer Center, Houston, TX). TKI-
resistant BV173 cells were generated by step-wise selection in the presence of increasing 
concentrations of imatinib, which induced the outgrowth of cells with the BCR-ABL1 T315I 
mutation. Experiments were performed on cell lines cultured for less than thirty passages. 
Mycoplasma was tested monthly following an established procedure (30). Cell lines were 
routinely authenticated by monitoring B-cell markers and BCR-ABL1 isoform expression. 
Cell lines were cultured in Iscove’s Medium (Gibco) supplemented with 10% fetal bovine 
serum, 100 U/mL penicillin–streptomycin and 2 mM L-glutamine at 37 °C. Primary human 
Ph+ ALL cells were maintained in SFEM (Stem Cell Technology) supplemented with SCF 
(40 ng/mL), Flt3L (30 ng/mL), IL-3 (10 ng/mL), IL-6 (10ng/mL) and IL-7 (10 ng/mL) 
(PeproTech). Information on primary Ph+ ALL samples used in this study is shown in 
Supplementary Table S1. 
 
Cell proliferation, cell cycle analysis and colony formation assay 
MTT assay was performed in 96-multiwell plates. Cells were incubated with 0.5 
mg/mL MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma 
Aldrich) at 37 °C for two hours; then, formazan crystals were dissolved with 0.1 M HCl in 
2-propanol and absorbance was measured at 570 nM. Cell cycle analyses were 
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performed by propidium iodide staining (50 g/mL) of cells permeabilized with 0.1% 
Triton, 0.1 % sodium citrate followed by flow cytometry determination of DNA content. For 
clonogenic assays, cells were pre-treated with 1 g/mL doxycycline (Research Product 
International) for 24 h or treated with drugs and immediately seeded in 1% 
methylcellulose medium (Stem Cell Technology) at 2,500-5,000 cells/mL. Colonies were 
counted after 7-10 days. 
 
Immunoblot 
Cells where counted and lysed at a density of 10,000/L in Laemmli Buffer. 
Lysates where run on polyacrylamide gels (Biorad), transferred onto nitrocellulose 
membranes and incubated with primary antibodies (described in Supplementary 
Methods) and HRP-conjugated secondary antibodies (ThermoFisher Scientific). Images 
where obtained by chemiluminescent reaction and acquisition on autoradiography films 
(Denville Scientific). Different antibodies where probed on the same nitrocellulose 
membrane; if necessary previous signals were removed by incubation in stripping buffer 
(62 mM Tris-HCl pH 6.8, 2 % SDS, -mercaptoethanol 0.7 %) for 20 minutes at 50 C or 
by incubation with 0.5 % sodium azide for 10 minutes at RT. 
 
Quantitative reverse-transcription PCR (qPCR) 
        RNA was isolated with RNeasy Plus Mini kit (Qiagen) and reverse-transcribed with 
High-Capacity cDNA Reverse Transcription Kit (ThermoFisher Scientific). 10 ng of cDNA 
was used as template and amplified with Power SYBR-Green PCR Master Mix 
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(ThermoFisher Scientific). When possible, primers were designed to span exon-exon 
junctions and are listed in the Supplementary Methods section. 
 
Lentiviral/retroviral vectors 
For MYB silencing, we used the MYB shRNA kindly provided by Dr. Tom Gonda 
(31). For silencing of p21 (the protein product of the CDKN1A gene), CDK4 and CDK6, 
the pLKO.1 plasmids constitutively expressing the shRNAs and conferring puromycin 
resistance were purchased from GE Dharmacon (pLKO.1-Scramble: Addgene #1864; 
p21 (CDKN1A) shRNA: GE Dharmacon #TRCN0000040125; CDK4 shRNA: GE 
Dharmacon #TRCN0000000363; CDK6 shRNA: GE Dharmacon #TRCN0000010081). 
For exogenous expression of CDK6, the RNA extracted from BV173 cells was reverse 
transcribed and the full-length cDNA corresponding to transcript variant 1 (NCBI: 
NM_001259.6) was PCR-amplified with a forward primer introducing the XbaI restriction 
site and a reverse primer introducing the BamHI site. Then the product was digested and 
inserted in the XbaI-BamHI sites of the lentiviral vector pUltra-hot developed by Dr 
Malcolm Moore (Addgene plasmid # 24130), which expresses the cDNA of interest and 
the mCherry protein as a bi-cistronic transcript under the control of the ubiquitin C 
promoter. The cyclin D3 cDNA (NCBI: NM_001760.4) was similarly obtained by total RNA 
purified from BV173 cells and inserted in the XbaI-BamHI sites of the pUltra-chili lentiviral 
vector (Dr Malcolm Moore, Addgene plasmid # 48687), which expresses dTomato as a 
reporter protein. To obtain a nucleus-localized CDK4 protein, CDK4 (NM_000075.3) was 
PCR amplified from BV173 cDNA by using a forward primer introducing an XbaI site and 
a reverse primer introducing a BamHI site following a sequence encoding the nuclear 
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localization signal from the SV40 large T antigen (CCAAAGAAGAAGCGTAAGGTA). The 
CDK4-NLS product was then inserted in the XbaI-BamHI sites of the pUltra-Hot vector. 
MYB cDNA was PCR amplified from the MigR1-MYB plasmid (32) and inserted into the 
XbaI-NheI sites of pUltra-hot. To obtain the shRNA-resistant MYB cDNA, the entire 
plasmid was amplified with primers harboring point mutations in the MYB sequence 
targeted by the shRNA, which were designed to preserve the integrity of the amino acid 
sequence of MYB. Then, the linear plasmid was self-ligated and sequenced to confirm 
that the expected mutations were introduced. The E308G mutation was introduced by a 
similar method. The pLXSP-BCL2 retrovirus was previously described (33). Lentiviral or 
retroviral VSV-G pseudo-typed particles were produced by calcium phosphate 
transfection of plasmid vectors into HEK-293T cells in combination with helper plasmids. 
24 hours later, the supernatant was collected, 0.45 μm-filtered and used to transduce 
BV173 or SUP-B15 cells by spinoculation in the presence of 8 μg/mL polybrene (Sigma-
Aldrich). Transduced cells where either FACS-purified on the basis of the fluorescent 
reporter protein or selected with 3 μg/mL puromycin (Sigma-Aldrich). 
 
Microarray Analysis 
MYB-shRNA SUP-B15 and BV173 cells were treated for 24 h with doxycycline or 
left untreated. RNA was isolated by using RNeasy Plus Mini kit (Qiagen). RNA was 
quantified on a Nanodrop ND-100 spectrophotometer, followed by RNA quality 
assessment by analysis on an Agilent 2200 TapeStation (Agilent Tehnologies). 
Fragmented, biotin labeled cDNA was synthesized using the Affymetrix WT Plus kit 
(Thermo Fisher Scientific) for BV173 cells or the Ovation PICO WTA-system V2 and 
 10 
cDNA biotin module (NuGen Technologies) for SUP-B15 cells. cDNA from BV173 cells 
was hybridized onto Affymetrix gene chips, Human Clariom S assays (ThermoFisher 
Scientific) and cDNA from SUP-B15 cells was hybridized onto Human Gene 1.0 ST Array 
(ThermoFisher Scientific) following the manufacturer instructions. Arrays were scanned 
on an Affymetrix Gene Chip Scanner 3000, using Command Console Software. Quality 
Control of the experiment was performed by Expression Console Software v1.4.1. Genes 
were considered differentially expressed when cDNA fold change was >1.5. Differentially 
expressed genes common to both data sets were used for pathway analysis using IPA 
software. Microarray data obtained in this study have been deposited in NCBI Gene 
Expression Omnibus under GEO Series accession number GSE105826. 
 
Immunofluorescence 
Cells were cytospun on poly-lysine coated glass slides, fixed with 3.7% 
formaldehyde, permeabilized with Triton 0.1% and incubated over-night at 4 C with 
primary antibodies anti-CDK4 or anti-CDK6 followed by Alexa Fluor 594-conjugated anti-
rabbit or anti-mouse secondary antibodies (ThermoFisher Scientific, 1 hour at room 
temperature) and then mounted with DAPI-Fluoromount G (Southern Biotech #0100-20). 
Imaging was acquired with a Nikon Eclipse Ti C2 laser confocal microscope with objective 
Plan Apo 60X/1.40 oil and processed with NIS Elements AR 4.5 software. 
 
Chromatin immunoprecipitation 
BV173 and SUP-B15 cells where processed with the SimpleChIP Enzymatic 
Chromatin IP KIT (Cell Signaling, #9002) following the manufacturer instruction.  
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Chromatin from 4x106 cells was used for each immunoprecipitation with specific primary 
antibodies or equal amounts of normal rabbit immunoglobulins. The purified DNA 
segments were quantified by qPCR and normalized to the amount of input material. 
 
Animals 
           Ph+ ALL cells (2x106 cells/mouse) were injected intravenously in 6-8 weeks old 
NOD/SCID-IL-2Rγ-null mice (Jackson Laboratory). Doxycycline was administered at 2 
g/L in the drinking water starting 7 days post injection. Peripheral blood leukemic cells 
were monitored by flow cytometry detection of GFP, human CD10 and/or CD19 (based 
on cell type specific expression). For immunoblot analysis, leukemic cells were purified 
from murine cells by FACS or with the EasySep™ Mouse/Human Chimera Isolation Kit 
(StemCell Technologies). Palbociclib (obtained by Pfizer) was dissolved at 15 mg/mL in 
50 mM sodium lactate, pH = 4.0 and given by oral gavage for 10 consecutive days at 150 
mg/kg. Sabutoclax (SelleckChem) was dissolved at 0.5 mg/mL in 10:10:80 Kolliphor-EL 
(Sigma-Aldrich)-ethanol-PBS and administered intraperitoneally every other day at 5 
mg/kg for a total of five doses. Animal experiments were approved by Thomas Jefferson 
University IACUC under protocol number 00012. 
 
Statistics 
        Results are expressed as means ± the standard error of the mean. Statistical 
significance was determined by unpaired two-tailed Student’s t-test. Bonferroni correction 
was applied in cases of multiple comparisons. Correlation studies were analyzed by the 
Pearson test and significance calculated by the Student’s t distribution. Significance in 
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survival experiment was assessed by the log-rank test. For drugs combination studies the 
combination index (CI) was calculated by the Chou-Talalay method (34) and synergism 
was defined as CI < 1. 
  
 13 
Results  
 
MYB silencing suppresses Ph+ ALL cell growth 
  We showed previously that loss of a Myb allele impairs colony formation of p190-
BCR-ABL1-transformed B-cell progenitors and suppresses B-cell leukemia in mice, but 
has no effect on normal B-cell development (15).  
To investigate if MYB is similarly required in Ph+ ALL, we assessed the effects of 
MYB silencing in human cell lines BV173, SUP-B15 and Z181 transduced with the 
doxycycline (DOX) inducible, GFP-expressing pLVTSH-MYB shRNA lentiviral vector 
(31). DOX treatment abolished MYB expression in the three cell lines (Fig. 1A, 
Supplementary Fig. S1A and S1B). Compared to controls, DOX-treated BV173 cells 
exhibited: i) cell cycle arrest in the G0/G1 phase (Fig. 1B); ii) growth inhibition revealed 
by MTT assays (Fig. 1C); and iii) reduced colony formation (Fig. 1D). These effects were 
also observed in SUP-B15 and Z181 cells (Supplementary Fig. S1C-E and S1F). These 
findings were not due to off-target effects, because expression of a MYB cDNA carrying 
synonymous point mutations on the shRNA target sequence (Supplementary Fig. S2A-
C) rescued the impaired proliferation and colony formation of MYB-silenced BV173 cells 
(Supplementary Fig. S2D and S2E). The effects of MYB silencing were also tested in TKI-
resistant T315I BV173 cells; as shown in Fig. 1E-H, growth suppression induced by DOX 
treatment was undistinguishable from that in parental BV173 cells.  As expected, 
treatment with imatinib or dasatinib markedly suppressed colony formation of parental 
BV173 cells but had no effect on the TKI-resistant derivative line (compare Fig. 1D and 
1H). 
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MYB silencing suppresses leukemia development in NOD/SCID-IL-2Rγ-null mice 
 Then, we assessed the requirement of MYB for leukemia development in 
NOD/SCID-IL-2Rγ-null (NSG) mice (35) injected with BV173 cells and treated with DOX. 
6-week post cell injection, DOX treatment induced a dramatic decrease of leukemia 
burden revealed by flow cytometry and cytokine-independent colony formation of bone 
marrow BV173 cells (Fig. 2A and 2B).  
  Mice injected with shMYB BV173 cells were also monitored for survival. 
Untreated mice died of leukemia (bone marrow heavily infiltrated by leukemic cells and 
splenomegaly) within 8 weeks (average survival = 42 days); mice given DOX to induce 
MYB silencing survived up to 200 days with no signs of disease, except for one animal 
whose cause of death could not be determined (Fig. 2C). All mice were sacrificed at the 
200th day endpoint and flow cytometry of bone marrow cells revealed no leukemic cells 
(Supplementary Fig. S3A), indicating that MYB silencing markedly suppressed or 
eradicated the disease. As expected, ectopic expression of shRNA-resistant MYB 
rescued the leukemogenesis of shMYB BV173 cells (Fig. 2C). 
DOX treatment also induced a marked increase in the survival of NSG mice 
injected with shMYB SUP-B15 cells. Control mice survived 53.0 ± 2.2 days; by contrast, 
one DOX-treated mouse died 115 days post-cell injection with no obvious signs of 
disease (<10% circulating leukemic cells and no evidence of splenomegaly) and 
remaining mice were sacrificed, when moribund, 139 to 163 days post-injection 
(Supplementary Fig. S3B). Interestingly, MYB expression was not silenced in bone 
marrow or spleen leukemia cell lysates from two terminally ill DOX-treated mice while one 
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sample displayed a shorter MYB isoform that may lack the shRNA target sequence 
(Supplementary Fig. S3C), likely explaining leukemia development in these animals. As 
control, MYB levels were markedly reduced in leukemic cells from a mouse injected with 
shMYB SUP-B15 cells and DOX-treated for 4 days, when peripheral blood GFP+ cells 
were > 50% (Supplementary Fig. S3C, lane 6). 
We also investigated the requirement of MYB in NSG mice injected with shMYB-
transduced patient-derived Ph+ ALL cells (ALL-674). For this experiment, transduced 
cells (approximately 10% GFP-positive) were expanded in a recipient NSG mouse, GFP-
sorted from the bone marrow and injected in female NSG recipient mice to obtain a more 
efficient engraftment (33). Leukemia progression was monitored by periodic analysis of 
total leukemic (CD19+) or shMYB-transduced (GFP+) cells. At 6 weeks, DOX-treated 
mice showed reduced numbers of CD19+ or GFP+ cells compared to untreated mice; 
however, by 10 weeks we observed an outgrowth of leukemic cells, a fraction of which 
was GFP-negative (Fig. 2D). In addition, among GFP+ cells, average GFP intensity was 
reduced (Fig. 2E) and MYB expression was not downregulated (Fig. 2F), suggesting 
selection of leukemic cells expressing low levels of the MYB shRNA. 
 
MYB modulates the expression of cell cycle regulatory genes 
         To investigate mechanisms responsible for the “MYB dependence” of Ph+ ALL 
cells, we performed microarray analysis of MYB silenced SUP-B15 and BV173 cells. 79 
genes were differentially expressed in both cell lines (Fig. 3A). Ingenuity pathway analysis 
revealed that cell cycle progression, DNA replication, and cell cycle checkpoints were the 
pathways most significantly affected by MYB silencing. In addition, BCL2 was also 
 16 
significantly down-regulated (Fig. 3A). qPCR analysis confirmed the down-regulation of 
CDK6, cyclin D3 (CCND3), CDK2, cyclin E2 (CCNE2), and FOXM1 and the up-regulation 
of the CDK inhibitor p21 (CDKN1A) (Fig. 3B and Supplementary Fig. S4A). Immunoblots 
of MYB-silenced BV173 and SUP-B15 cells confirmed the increase in p21 expression 
and the down-regulation of CDK6 and cyclin D3 (Fig. 3C and 3D); these changes were 
associated with markedly reduced CDK4/6-dependent RB phosphorylation (36,37) and 
expression of FOXM1 (Fig. 3C and 3D), a CDK4/6 substrate stabilized through 
phosphorylation (38).  Expression of RB was partially reduced in MYB-silenced cells; 
instead, levels of p130-RBL2 were increased and the protein migrated faster than in 
untreated cells consistent with loss of phosphorylation (Fig. 3C and 3D). These changes 
were confirmed in MYB silenced ALL-674 cells purified from the bone marrow of two DOX-
treated (4 days) mice (Fig. 3E). By chromatin immunoprecipitation (ChIP) in BV173 (Fig. 
4A-C) and SUP-B15 cells (Supplementary Fig. S4B), we detected binding of MYB to the 
promoter of the CDKN1A and CCND3 genes and to the promoter and intron 5 enhancer 
of the CDK6 gene (39). These regions contain putative MYB-binding sites, suggesting 
that CDK6, cyclin D3 and p21 expression is directly regulated by MYB. As a positive 
control, MYB was detected at the promoter of the BCL2 gene in BV173 and SUP-B15 
cells (Supplementary Fig. S4C). To further investigate the significance of these findings, 
mRNA levels of MYB and its putative targets were analyzed in 24 primary human Ph+ 
ALL samples. We observed a strikingly positive correlation between MYB and CDK6 
expression (p = 0.00008) whereas that between MYB and cyclin D3 or p21 was not 
significant after Bonferroni correction (Fig. 4D-F). A positive correlation between MYB and 
CDK6 expression was also noted in 226 samples of adult B-cell ALL (40) (Fig. 4G), in 
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207 samples of Ph-negative, high-risk childhood ALL (41) (Fig. 4H), and in 174 AML 
samples from The Cancer Genome Atlas (Fig. 4I). 
 
CDK6 but not CDK4 expression is necessary for Ph+ ALL cell proliferation  
          In MYB-silenced BV173 and SUP-B15 cells, expression of CDK6 is markedly 
downregulated while levels of CDK4 are not affected (Fig. 5A and 5B). Since CDK4 and 
CDK6 should have redundant roles in G1-S phase transition and CDK4 is expressed in 
most cases of Ph+ ALL (Fig. 5C), we asked whether decreased CDK6 levels can explain 
the cell cycle arrest of MYB-silenced cells. Thus, BV173 and SUP-B15 cells were 
transduced with CDK4 or CDK6 shRNAs. Surprisingly, CDK4 silencing had negligible 
effects while CDK6 silencing suppressed cell cycle progression, RB phosphorylation and 
FOXM1 expression in both lines (Fig. 5D-G). These data suggest that in Ph+ ALL cells 
CDK6 exerts a function that is not shared by CDK4. Interestingly, confocal microscopy 
analysis revealed that CDK6 is predominantly localized in the nucleus of Ph+ ALL cells, 
while CDK4 is almost exclusively cytoplasmic (Fig. 5H). To investigate whether the 
cytoplasmic localization of CDK4 may explain its inability to rescue the growth 
suppression induced by CDK6 silencing, a nucleus-localized form of CDK4 (CDK4-NLS) 
was expressed in BV173 shMYB cells transduced with a lentiviral vector expressing cyclin 
D3 (since the latter is also down-regulated in MYB silenced cells).  In cells expressing 
cyclin D3 alone, CDK4 was predominantly cytoplasmic; by contrast, CDK4 was mostly 
nuclear in cells expressing CDK4-NLS (Supplementary Fig. S5A).  Upon DOX treatment 
to silence MYB expression, co-expression of cyclin D3 and CDK4-NLS partially restored 
RB phosphorylation and FOXM1 expression (Supplementary Fig. S5B) and resulted in a 
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significant increase in the percentage of proliferating cells (Supplementary Fig. S5C) 
compared to empty vector (EV) transduced cells. 
 
Restoring expression of CDK6, cyclin D3 and BCL2 rescues cell cycle arrest and 
apoptosis induced by MYB silencing 
          Next, we asked whether restoring the expression of cyclin D3 and CDK6 would be 
sufficient to rescue the proliferative arrest of MYB silenced cells.  
    Expression of CDK6 alone partially restored RB phosphorylation and rescued FOXM1 
expression whereas expression of cyclin D3 alone did not (Supplementary Fig. S6A). 
CDK6 expression partially rescued the reduced growth of MYB-silenced cells whereas 
cyclin D3 expression had a modest effect (Supplementary Fig. S6B). 
Co-expression of CDK6 and cyclin D3 (K6/D3) restored RB phosphorylation and 
FOXM1, CDK2 and cyclin E2 (CCNE2) expression (Fig. 6A-C), and rescued the cell cycle 
arrest of cells treated with DOX for two days (Fig. 6D and 6E). However, MYB silenced 
K6/D3 cells grew less vigorously after four days of DOX treatment (Fig. 6F), and did not 
form colonies in methylcellulose (Fig. 6G). 
Based on these findings, we asked whether induction of apoptosis could explain 
the reduced growth of MYB-silenced K6/D3 BV173 cells. Indeed, while sub-G1 apoptotic 
cells were not detected by cell cycle analysis of shMYB BV173 or SUP-B15 cells 
performed after two days of DOX treatment (Fig. 1B, 1F, 6D, 6E and Supplementary Fig. 
S1B), a 4-day DOX treatment increased the percentage of Annexin V+ cells and induced 
Caspase-3 cleavage in EV and K6/D3 cells (Fig. 6H, I).  
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BCL2 was previously reported to be a MYB target (42-45) and thus its decreased 
expression may contribute to the apoptosis of MYB-silenced cells (Fig. 6J, K). To test this 
hypothesis, we generated a derivative shMYB BV173 K6/D3 cell line named KDB in which 
levels of ectopically expressed BCL2 were not affected by MYB silencing (Fig. 6L). In 
these cells, BCL2 expression inhibited apoptosis, restored cell growth and partially 
rescued the loss of colony formation induced by MYB silencing (Fig. 6M-O).   
 The defective colony formation potential of MYB-silenced KDB cells was not 
caused by increased p21 expression because silencing p21 did not further increase 
colony formation of DOX-treated KDB cells (Supplementary Fig. S6C-F). 
Finally, we tested whether these derivative lines induce leukemia in NSG mice.  
Mice injected with shMYB BV173 cells expressing K6/D3 or BCL2 alone and given DOX 
did not develop leukemia. However, 10 of 12 DOX-treated mice injected with KDB or 
KDBp cells developed leukemia and 9 of them succumbed to the disease by 200 days 
(Fig. 6P). 
  
The recruitment of p300/CBP is required for MYB dependent control of proliferation 
but is dispensable for its anti-apoptotic effects 
The interaction between MYB and the histone acetyl-transferases p300/CBP is 
critically important for MYB function in hematopoietic cells (46-48). To assess the 
importance of p300/CBP recruitment for MYB transcriptional effects, shMYB BV173 cells 
were transduced with the EV, the shRNA-resistant wild type (WT) MYB or the shRNA-
resistant MYB-E308G mutant that does not interact with p300/CBP (48) and treated with 
DOX to silence endogenous MYB. 
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While expression of shRNA-resistant MYB WT completely rescued the effects of 
MYB silencing, DOX-treated MYB-E308G expressing cells displayed decreased S phase 
and colony formation but no increase in Annexin V positivity (Supplementary Fig. S7A-
C). By immunoblot analysis, expression of MYB-E308G rescued levels of BCL2 but not 
CDK6 and FOXM1 or RB phosphorylation (Supplementary Fig. S7D). To investigate 
mechanisms that may explain the differential requirement of p300/CBP in the regulation 
of CDK6 and BCL2, ChIP experiments were performed at the regulatory regions of these 
genes. 
DOX-treated EV-transduced cells showed reduced levels of MYB and p300 
binding and H3K27 acetylation at the promoter and enhancer of CDK6 and at the 
promoter of BCL2, compared to cells expressing MYB-WT. MYB-E308G-expressing cells 
also showed reduced p300 binding and H3K27 acetylation at the promoter and enhancer 
of CDK6, but H3K27 acetylation was not reduced at the BCL2 promoter, in spite of lower 
p300 binding (Supplementary Fig. S7E-G). 
 
 Co-treatment with the CDK4/6 inhibitor palbociclib and a BCL2 antagonist inhibits 
growth of Ph+ ALL cells ex vivo and suppresses leukemia burden in NSG mice 
 Based on their essential role in cell growth, CDK6 and BCL2 might serve as 
targets to exploit the MYB “addiction” of Ph+ ALL cells. First, we investigated the effects 
of the CDK4/CDK6 inhibitor palbociclib in primary Ph+ ALL cells. Similar to its effects in 
cell lines (49), palbociclib inhibited the S phase of Ph+ ALL cells (Supplementary Fig. 
S8A). Moreover, it suppressed colony formation of primary Ph+ ALL cells whereas normal 
CD34+ cells were less affected (Supplementary Fig. S8B). Then, we assessed the effect 
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of palbociclib in NSG mice injected with three different Ph+ ALL samples. Compared to 
vehicle-treated mice, drug-treated animals displayed lower numbers of peripheral blood 
CD19+ leukemia cells 6-8 weeks post-cell injection (Supplementary Fig. S8C). However, 
the effect was transient, probably reflecting the cytostatic effects of palbociclib and/or the 
insufficient length of the treatment.  
To mimic more faithfully the effects of MYB silencing, we used palbociclib in 
combination with the BCL2 antagonist venetoclax (50). The palbociclib/venetoclax 
combination had synergistic effects in BV173 and additive effects in SUP-B15 cells 
(Supplementary Fig. S9A-D). SUP-B15 cells were markedly more sensitive to venetoclax 
than BV173 cells (Supplementary Fig. S9E and S9F), likely because of lower MCL1 and 
BCL-XL and higher BIM expression (Supplementary Fig. S9G). Primary Ph+ ALL cells 
display low proliferation in vitro, preventing analysis of the effects induced by the 
palbociclib/venetoclax combination. However, treatment with venetoclax induced 
apoptosis in three Ph+ ALL samples, albeit at different drug concentrations 
(Supplementary Fig. S9H-J). In particular, sample #1006 was resistant to treatment with 
venetoclax, most likely because of much higher BCL-XL and MCL1 levels than in the 
other samples (Supplementary Fig. S9K).  
Due to the sample-to-sample variability in expression of BCL2 family members and 
sensitivity to venetoclax, we tested the effects of the pan-BCL2 inhibitor sabutoclax (51). 
Treatment with the palbociclib/sabutoclax combination synergistically reduced the 
number of BV173 and SUP-B15 cells at most doses (Supplementary Fig. S9L-M and 
S9N-O, respectively).  
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          Next, we evaluated the effect of the palbociclib/sabutoclax combination on 
leukemia progression in NSG mice injected with ALL-674 or ALL-1222 cells.  
 Treatment with palbociclib induced a moderate reduction in peripheral blood 
leukemia burden (17% and 32% decrease in ALL-674 and ALL-1222 samples, 
respectively) while treatment with sabutoclax had negligible effects. However, the 
combined treatment was significantly more effective than either drug alone (77% 
reduction for ALL-674, Fig. 7A and 7B and 90% reduction for ALL-1222, Fig. 7C and 7D) 
in suppressing leukemia load.  
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Discussion   
 We show here that MYB expression is critically important for growth and 
leukemogenesis of Ph+ ALL cells. Mechanistically, the effects of MYB depend on 
transcriptional regulation of many targets, among which CDK6 and BCL2 are crucial 
mediators of its proliferative and anti-apoptotic functions.  
In addition to MYB-dependent regulation, several mechanisms may contribute to 
enhanced expression/activity of CDK6 in Ph+ ALL. The CDK4/6 inhibitor INK4A is 
structurally altered in 30-50% of Ph+ ALL (11,52), the CDK6 promoter is hypomethylated 
in BCR-ABL1 transformed cells (53), and miR-124 is epigenetically silenced in Ph+ ALL, 
resulting in higher CDK6 levels (54).  In addition to its kinase-dependent effects, CDK6 is 
also involved in transcriptional regulation (55,56). 
 Silencing CDK6 (but not CDK4) alone suppressed S phase entry of Ph+ ALL cells; 
however, this effect may not require kinase-independent mechanisms since it was 
undistinguishable from that induced by pharmacological inhibition of CDK4/6. The 
essential role of CDK6 was noted in MLL-rearranged leukemias (57,58), but no 
explanation was provided for the differential requirement of CDK4 and CDK6. Here we 
show that CDK6 is readily detectable in the nucleus of Ph+ ALL cells while CDK4 is almost 
exclusively cytoplasmic. The exclusion of CDK4 from the nucleus likely explains its 
inability to compensate for the growth inhibition induced by CDK6 downregulation since 
expression of a nucleus-localized form of CDK4, in combination with cyclin D3 
expression, partially rescued the impaired proliferation of MYB-silenced cells. 
We do not know the reasons for the lack of nuclear import of CDK4 in Ph+ ALL 
cells. A possible explanation might reside in the expression levels of different cyclin D 
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proteins since CDK4 appears to interact preferentially with cyclin D1 whereas CDK6 binds 
preferentially to cyclin D3 (59) and levels of cyclin D3 mRNA are much higher than those 
of cyclin D1 in BV173 and SUP-B15 cells, based on microarray data. This may affect both 
nuclear import and kinase activity of CDK4. 
          Interestingly, MYB expression is required for leukemogenesis in a model of MLL-
AF9 AML (22) and MLL-rearranged ALL and AML cells are also dependent on CDK6 but 
not CDK4 expression (57,58). Furthermore, MYB and CDK6 expression is highly 
correlated in ALL and in adult AML, suggesting that MYB might link different oncogenic 
pathways to the activation of CDK6 expression. 
  Decreased susceptibility to apoptosis mediated by BCL2 is also important for 
MYB-dependent regulation of Ph+ ALL cell growth. However, even in combination with 
CDK6/Cyclin D3, BCL2 enabled MYB-deficient BV173 cells to develop leukemia only after 
long latency, suggesting that other MYB regulated pathways are important for a complete 
recovery of the leukemogenic potential of these cells. 
 A critical mechanism whereby MYB regulates gene expression is through its 
interaction with p300/CBP, since mutations of MYB in the p300/CBP binding sites 
phenocopy the impaired hematopoiesis induced by MYB knockout and prevent leukemia 
formation (46-48). The MYB-p300 interaction seems necessary for CDK6 expression and 
cell cycle progression but not for regulation of BCL2 expression and cell survival. Thus, 
drugs that disrupt this interaction might have limited efficacy in Ph+ ALL unless MYB-
regulated anti-apoptotic pathways effects are also targeted. 
Our approach of simultaneously inhibiting MYB dependent proliferative and anti-
apoptotic programs recapitulates more faithfully the effects of MYB silencing in Ph+ ALL, 
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as indicated by the more potent suppression of ex vivo and in vivo cell growth by 
combining palbociclib with venetoclax or sabutoclax. Of interest, venetoclax treatment of 
patient-derived Ph+ ALL cells revealed sample-to-sample variations in induction of 
apoptosis. These findings likely depend on the expression profile of BCL2 family 
members and suggest that the choice of a particular BCL2 antagonist in the clinic should 
be guided by the pattern of BCL2 family expression and the ex vivo drug sensitivity of 
Ph+ leukemia cells from individual patients. 
On the other hand, given that CDK4 is dispensable in Ph+ ALL, CDK6-selective 
inhibitors might prove as effective as dual CDK4/6 inhibitors in blocking the proliferation 
of Ph+ ALL cells and may cause fewer side effects in normal cells. 
In conclusion, our data indicate that targeting CDK6 and BCL2 is an effective 
strategy to exploit therapeutically the MYB addiction of Ph+ ALL cells and might provide 
an alternative treatment for patients who develop resistance to TKI-based therapies. 
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Figures and Figure Legends 
 
Figure 1. MYB silencing reduces viability and proliferation of Ph+ ALL BV173 cell 
line and of its TKI-resistant (T315I) derivative. A-C, immunoblot (A), cell cycle analysis 
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at 48 hours of treatment (B) and cell growth at the indicated times (C) of untreated or 
DOX-treated BV173 shMYB cells; D, methylcellulose colony formation assay of BV173 
shMYB cells untreated, treated with DOX to induce MYB silencing (shMYB), imatinib 1 
M (IM) or dasatinib 2 nM (DAS); E-H, experiments performed as in A-C on the TKI-
resistant cell line T315I BV173 shMYB. 
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Figure 2. MYB silencing suppresses leukemogenesis of Ph+ ALL cells in 
immunodeficient mice. A, and B, leukemia burden in untreated or DOX-treated NSG 
mice (n = 4) injected with BV173 shMYB cells assessed by flow cytometry analysis of 
GFP-positive bone marrow cells (A) or methylcellulose colony formation assay (B); C, 
Kaplan-Meier survival plot of untreated or DOX-treated NSG mice injected with BV173 
shMYB cells or with BV173 shMYB cells expressing a shMYB-resistant form of MYB; D, 
peripheral blood leukemia burden (percentage of GFP+ or CD19+ cells) in untreated (n = 
6) or DOX-treated (n = 5) NSG mice injected with primary Ph+ ALL (#674) cells 
transduced with the shMYB lentivirus; E, flow cytometry analysis of GFP positivity in the 
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bone marrow of terminally ill untreated or DOX-treated NSG mice injected with ALL-674 
shMYB cells (gated to exclude GFP-negative cells, plot display one representative 
untreated and one DOX-treated mouse); F, immunoblot of MYB expression in GFP-sorted 
bone marrow cells from NSG mice injected with ALL-674 shMYB cells and continuously 
treated with DOX for 11 weeks (lanes 2-4) or after a four-day (4D) treatment initiated 
when peripheral blood GFP-positive cells were >50% (10 weeks post-injection). 
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Figure 3. MYB silencing alters the expression of cell cycle regulatory genes. A, 
heatmap of 79 genes significantly modulated in BV173 shMYB and SUP-B15 shMYB cell 
lines (C1, C2 and C3 denote untreated controls, D1, D2 and D3 denote samples treated 
with DOX for 24 h); B, qPCR analysis of CDK6, cyclin D3 (CCND3), p21 (CDKN1A), 
CDK2, cyclin E2 (CCNE2), and p21 (CDKN1A) expression in BV173 shMYB cells 
untreated or DOX-treated for the indicated time points (normalized to GAPDH); C-E, 
immunoblot analysis of cell cycle-regulatory genes in MYB-silenced Ph+ cell lines (C and 
D) or ALL-674 shMYB cells DOX-treated for 4 days in vivo and GFP-sorted (E). 
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Figure 4. MYB regulates the expression of cell cycle regulatory genes and is co-
expressed with CDK6 in different types of leukemia. A-C, MYB binding by ChIP to 
regulatory regions of the CDK6 (A), CCND3 (B) or CDKN1A genes (C) in BV173 cells 
(numbers refer to the position of the forward primer relative to the TSS). As negative 
controls, ChIPs were performed with a non-targeting antibody (white bars) or with an anti-
MYB antibody on lysates from MYB-silenced BV173 cells (grey bars); D-F, plot of the 
 39 
correlation between the mRNA levels (by qPCR) of MYB and CDK6 (D), MYB and CCND3 
(E) or MYB and CDKN1A (F) in 24 samples of primary human Ph+ ALL samples; G, plot 
of the correlation between the expression (by microarray) of MYB and CDK6 in a panel 
of 226 B-cell ALL of mixed cytogenetics (GSE79533); H, plot of the correlation between 
the expression (by microarray) of MYB and CDK6 in a panel of 207 Ph-negative 
childhood, high-risk ALL (GSE11877); I, plot of the correlation between the expression of 
MYB and CDK6 based on TCGA data on 174 samples of acute myeloid leukemia (AML) 
of mixed cytogenetics (RNA-seq, median expression). 
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Figure 5. Expression of CDK6 but not CDK4 is required for the proliferation of Ph+ 
ALL cells. A-C, immunoblot of CDK6 and CDK4 expression in untreated or DOX-treated 
BV173 shMYB cells (A) or SUP-B15 shMYB cells (B) and in untreated primary Ph+ ALL 
cells (C); D, and E, representative experiment showing the cell cycle analysis of scramble, 
CDK4, or CDK6 constitutive shRNA-transduced BV173 (D) or SUP-B15 cells (E). 
Compared to scramble-transduced cells, the decrease in the percentage of S phase cells 
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is significant in BV173 shCDK6 cells (p = 10-5) and in SUP-B15 shCDK6 cells (p = 0.001), 
but not in BV173 shCDK4 or SUP-B15 shCDK4 cells (results are from three independent 
experiments); F, and G, immunoblot analysis of CDK4, CDK6, RB phosphorylation and 
FOXM1 expression in scramble, CDK4 or CDK6 shRNA-transduced BV173 (F) or SUP-
B15 cells (G); H, subcellular localization of CDK6 (left panels) or CDK4 (right panels) in 
BV173, SUP-B15 and primary human Ph+ ALL cells (ALL-1222 and ALL-3934) by 
immunofluorescence-confocal microscopy (scale bar = 20 M). 
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Figure 6. Co-expression of CDK6/Cyclin D3 and BCL2 partially rescues the effects 
of MYB silencing. A, immunoblot for MYB and its targets in untreated or DOX-treated 
(96 h) BV173 shMYB EV or BV173 shMYB K6/D3 cells. B, and C, qPCR for CDK2 (B) 
and Cyclin E2 (C) in untreated or DOX-treated (48 h) BV173 shMYB EV cells or BV173 
shMYB K6/D3 cells; D, and  E, cell cycle analysis of untreated or DOX-treated (48 h) 
BV173 shMYB EV (D) or BV173 shMYB K6/D3 cells (E); F, cell growth by MTT assay of 
untreated or DOX-treated BV173 shMYB EV cells or BV173 shMYB K6/D3 cells (vertical 
axis is shown as a logarithmic scale); G, colony assay of untreated or DOX-treated BV173 
shMYB K6/D3 cells; H, and I, Annexin V positivity (top) and expression of cleaved 
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caspase 3 by immunoblot (bottom) in untreated or DOX-treated (2, 4, or 6 days) BV173 
shMYB EV (H) and BV173 shMYB K6/D3 cells (I); J, and K, qPCR for BCL2 (top) and 
immunoblot for BCL2 (bottom) in untreated or DOX-treated (2 or 4 days) BV173 shMYB 
EV (J) or BV173 shMYB K6/D3 cells (K); L, immunoblot of EV and KDB derivative BV173 
shMYB cell lines untreated or treated with DOX for 4 days; M-O, Annexin V positivity (M), 
cell growth by MTT assay (N, vertical axis is shown as a logarithmic scale) and 
methylcellulose colony formation assay (O) of untreated or DOX-treated KDB cells; P, 
Kaplan-Meier survival plot of NSG mice injected with untreated BV173 shMYB or DOX-
treated BV173 shMYB derivative cell lines. 
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Figure 7. Sabutoclax and palbociclib cooperate to suppress Ph+ ALL in NSG mice. 
A, and B, percentage of CD19+ cells in the peripheral blood (A) and fold-changes in 
leukemia burden (B) of untreated and drug-treated NSG mice injected with sample ALL-
674 before (5 weeks post injection) and after treatment (7 weeks post injection); C, and 
D, percentage of CD19+CD10+ cells in the peripheral blood (C) and fold-changes in 
leukemia burden (D) of untreated and drug-treated NSG mice injected with sample ALL-
1222 before (5 weeks post injection) and after treatment (7 weeks post injection); 
palbociclib was given by oral gavage for 10 consecutive days at 150 mg/kg while 
sabutoclax was administered intraperitoneally every other day (five doses, 5 mg/kg). 
